WO2013169273A1 - Synergistic selenopeptide formulations for the protection of dermal papilla cells - Google Patents

Synergistic selenopeptide formulations for the protection of dermal papilla cells Download PDF

Info

Publication number
WO2013169273A1
WO2013169273A1 PCT/US2012/038772 US2012038772W WO2013169273A1 WO 2013169273 A1 WO2013169273 A1 WO 2013169273A1 US 2012038772 W US2012038772 W US 2012038772W WO 2013169273 A1 WO2013169273 A1 WO 2013169273A1
Authority
WO
WIPO (PCT)
Prior art keywords
dermal papilla
concentrate
papilla cells
para
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/038772
Other languages
English (en)
French (fr)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to RU2014144521A priority Critical patent/RU2606752C2/ru
Priority to CA2872535A priority patent/CA2872535C/en
Priority to BR112014027717A priority patent/BR112014027717A2/pt
Priority to MX2014013460A priority patent/MX355546B/es
Publication of WO2013169273A1 publication Critical patent/WO2013169273A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to protective compositions for dermal papilla cells. More specifically, the present invention relates to formulations comprising synergistic compositions that include (a) ⁇ -glucogallin or ⁇ -glucogallin and gallates, (b) concentrate of liquid endosperm of Cocos nucifera and (c) selenopeptides, for the protection of dermal papilla cells.
  • Dermal papilla cells are mesenchymal cells of the skin that not only regulate development of a hair peg but also constitute a reservoir of multi-potent stem cell lineages (Driskell et al., 2011). These stem cell lineages function as "tissue engineers" and are valued assets in regenerative medicine. Dermal papilla cells expressing the stem cell marker genes Sox 2 (transcription factor essential for the preservation of the pluripotent phenotype of stem cells) evince ability to self renew, induce hair peg formation and differentiate into fibroblasts that aid the formation of skin extracellular matrix, hi fact, dermal papilla plays a very vital role in replacement of senescent fibroblasts with healthy ones thereby maintaining fibroblast numbers.
  • Sox 2 transcription factor essential for the preservation of the pluripotent phenotype of stem cells
  • compositions comprising compositions that include (a) l-O-galloyl-P-D-glucose ( ⁇ -glucogallin) or ⁇ -glucogallin and gallates, and (b) concentrate of liquid endosperm of Cocos nucifera.
  • the present invention discloses formulations comprising synergistic compositions including (a) ⁇ -glucogallin or ⁇ -glucogallin and gallates (b) concentrate of liquid endosperm of Cocos nucifera and (c) selenopeptides for the protection of dermal papilla cells from stress signals.
  • FIG.l shows the photomicrographs of 0.5% concentrate of liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40%w/w of total dissolved solids unable to protect dermal papilla cells singly.
  • FIG.2 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-1 (compositions comprising at least 10% w/w of l-O-galloyl- ⁇ - D-glucose ( ⁇ -glucogallin) in comparison with UVB irradiated untreated cells.
  • PC-1 is unable to protect dermal papilla cells from UVB dosage above 0.43 J/cm 2 .
  • Cell damage in PC-1 treated cells occurs at UVB dosage of 0.648 J/cm (shown as part of FIG.4).
  • FIG.3 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-2 (compositions comprising at least 10% w/w of l-O-galloyl- ⁇ - D-glucose ( ⁇ -glucogallin) and 50% to greater than 50% w/w of gallates) in comparison with UVB irradiated untreated cells.
  • PC-2 is unable to protect dermal papilla cells from UVB dosage above 0.43 J/cm .
  • Cell damage in PC-2 treated cells occurs at UVB dosage of 0.648 J/cm (shown as part of FIG.5).
  • FIG.4 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-3 (PC-1+0.5% concentrate of liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40% w/w of total dissolved solids).
  • PC-3 protects dermal papilla cells from UVB exposure levels of up to only 0.648 J/cm and not 0.8
  • FIG.5 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-4 (PC-2+0.5% concentrate of liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40%w/w of total dissolved solids).
  • PC-4 protects dermal papilla cells at UVB exposure levels of only up to 0.648 J/cm 2 and not 0.8 J/cm 2. Cell death at 0.8 J/cm is shown in the figure.
  • FIG.6 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-5 (PC-3 + 0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine).
  • PC-5 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 0.8 J/cm 2"
  • FIG.7 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-6 (PC-3 + 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine).
  • PC-6 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 1.0 J/cm 2 .
  • FIG.8 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-7 (PC-4+0.001%w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine).
  • PC-7 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 0.8 J/cm 2 .
  • FIG.9 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-8 (PC-4+0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine).
  • PC-8 provides significant (95%) protection to dermal papilla cells exposed to very high doses of UVB radiation of 1.0 J/cm 2 .
  • FIG.10 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-9 (0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine (FIG.lOa) or 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine (FIG.lOb)).
  • PC-9 provides no protection to dermal papilla cells exposed to even low level of UVB radiation (UVB dose of 0.432 J/cm 2 ).
  • the present invention relates to dermal papilla cell protective formulation comprising synergistic composition, said composition including l-O-galloyl-P-D-glucose ( ⁇ - glucogallin), concentrate of liquid endosperm of Cocos nucifera and selenopeptides.
  • the synergistic composition comprises at least 10% w/w of l-O-galloyl-P-D-glucose ( ⁇ -glucogallin).
  • the synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40% w/w of total dissolved solids.
  • the synergistic composition comprises 0.001% w/w of selenopeptides.
  • the selenopeptide is ⁇ -L-glutamyl- Selenomethyl-L-selenocysteine.
  • the selenopeptide is ⁇ -L-glutamyl-L- Selenomethionine.
  • the present invention relates to dermal papilla cell protective formulation comprising synergistic composition, said composition including l-O-galloyl-P-D-glucose ( ⁇ - glucogallin) and gallates, concentrate of liquid endosperm of Cocos nucifera and selenopeptides.
  • the synergistic composition comprises at least 10% w/w of l-O-galloyl- -D-glucose ( ⁇ -glucogallin) and 50% to greater than 50% total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1 -methyl ester 2-O-gallate and ellagic acid.
  • the synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40% w/w of total dissolved solids.
  • the synergistic composition comprises 0.001% w/w of selenopeptides.
  • the selenopeptide is ⁇ -L-glutamyl- Selenomethyl-L-selenocysteine.
  • the selenopeptide is ⁇ -L-glutamyl-L- Selenomethionine.
  • the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact the dermal papilla cells and the protective formulations as claimed in claims 1 or 7.
  • the present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact the dermal papilla cells and the protective formulation as claimed in claims 1 or 7.
  • the dermal papilla cells include dermal stem/progenitor cells.
  • the present invention relates to the following synergistic selenopeptide formulations for the protection of dermal papilla cells.
  • PC-5 comprising synergistic compositions, said compositions including (a) 1- O-galloyl-p-D-glucose ( ⁇ -glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine.
  • compositions comprise (a) at least 10% w/w l-O- galloyl-P-D-glucose ( ⁇ -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L- glutamyl-Selenomethyl-L-selenocysteine.
  • PC-6 comprising synergistic compositions, said compositions including (a) 1- O-galloyl-p-D-glucose ( ⁇ -glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl-L- Selenomethionine.
  • compositions comprise (a) at least 10% w/w 1- O-galloyl-p-D-glucose ( ⁇ -glucogallin); (b) 0.5% w/w of concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine.
  • PC-7 comprising synergistic compositions, said compositions including, (a) 1- O-galloyl ⁇ -D-glucose ( ⁇ -glucogallin) and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl- Selenomethyl-L-selenocysteine.
  • said compositions comprise (a) at least 10% w/w of l-O-galloyl ⁇ -D-glucose ( ⁇ -glucogallin) and 50% to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6- methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w of concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine.
  • PC-8 comprising synergistic compositions, said compositions including, (a) 1-
  • compositions comprise (a) at least 10% w/w of
  • the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-5 comprising synergistic compositions, said compositions including, (a) l-O-galloyl-P-D-glucose ( ⁇ - glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine.
  • compositions comprise (a) at least 10% w/w of l-O-galloyl-p-D-glucose ( ⁇ - glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine.
  • the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-6 comprising synergistic compositions, said compositions including, (a) l-O-galloyl-p-D-glucose ( ⁇ - glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl-L-Selenomethionine.
  • said compositions comprise (a) at least 10% w/w of 1 -O-galloyl-P-D-glucose ( ⁇ - glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L-glutamyl-L- Selenomethionine.
  • the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-7 comprising synergistic compositions, said compositions including, (a) l-O-galloyl- -D-glucose ( ⁇ - glucogallin)and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine.
  • compositions including, (a) l-O-galloyl- -D-glucose ( ⁇ - glucogallin)and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl-Selenomethyl-L-selenoc
  • said compositions comprise (a) at least 10% w/w of l-O-galloyl- -D- glucose ( ⁇ -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1 -methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine.
  • the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-8 comprising of synergistic compositions, said compositions including, (a) l-O-galloyl- -D-glucose ( ⁇ - glucogallin) and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl-L-Selenomethionine.
  • said compositions comprise (a) at least 10% w/w of l-O-galloyl ⁇ -D- glucose ( ⁇ -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1 -methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine.
  • the present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-5 comprising synergistic compositions, said compositions including, (a) l-O-galloyl-P-D-glucose ( ⁇ -glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl- Selenomethyl-L-selenocysteine.
  • compositions comprise (a) at least 10% w/w of l-O-galloyl ⁇ -D-glucose ( ⁇ -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine.
  • the present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-6 comprising synergistic compositions, said compositions including, (a) l-O-galloyl-P-D-glucose ( ⁇ -glucogallin); (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) ⁇ -L-glutamyl-L- Selenomethionine.
  • compositions comprise (a) at least 10% w/w of l-O-galloyl-P-D-glucose ( ⁇ -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine.
  • the present invention also relates to a method of maintaining morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-7 comprising synergistic compositions, said compositions including, (a) ⁇ - glucogallin and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine.
  • said compositions comprise (a) at least 10%» w/w of l-O-galloyl-P-D- glucose ( ⁇ -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1 -methyl ester 2-O-gallate and ellagic acid; (b) 0.5%» w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) 0.001%» w/w of ⁇ -L-glutamyl-Selenomethyl-L- selenocysteine.
  • the present invention also relates to a method of maintaining the morphology and viable numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-8 comprising of synergistic compositions, said compositions including, (a) ⁇ -glucogallin and gallates; (b) concentrate of liquid endosperm of Cocos nucifera, said concentrate including atleast 40% dissolved solids; and (c) ⁇ -L-glutamyl-L- Selenomethionine.
  • said compositions comprise (a) at least 10% w/w of l-O-galloyl ⁇ -D-glucose ( ⁇ -glucogallin) and 50%» w/w to greater than 50%» w/w of total gallates including mucic acid 1, 4-lactone-5-0-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1 -methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of Cocos nucifera, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of ⁇ -L-glutamyl-L-Selenomethionine.
  • the dermal papilla cells mentioned herein above comprise dermal stem progenitor cells.
  • UVB dosages ranging from 0.0072 J/cm 2 to 1.0 J/cm 2 (stress si *gnal) wi ⁇ th or without sample (protective formulations) treatment. After exposure, the cells were incubated in a C0 2 incubator for 48 hours and developed by NRU (Neutral Red Uptake) staining techniques to analyze cell viability. The absorbance due to viable cells is read at 492nm in a micro plate reader.
  • FIG.l shows that the 0.5% concentrate of liquid endosperm of Cocos nucifera, said concentrate comprising not less than 40%w/w of total dissolved solids is unable to protect dermal papilla cells singly at 0.43 J/cm 2 and 0.648 J/cm 2 UVB exposure levels.
  • FIG.2 shows PC-1 by itself is able to protect dermal papilla cells from UVB exposure levels of only up to 0.43 J/cm .
  • FIG.3 shows PC-2 by itself is able to protect dermal papilla cells from UVB exposure levels of only up to 0.43 J/cm .
  • FIG.4 shows that PC-3 is able to protect dermal papilla cells from UVB exposure levels of up to 0.648 J/cm 2 and death of PC-3 treated dermal papilla cells is seen at UVB exposure level of 0.8 J/cm .
  • FIG.5 shows that PC-4 is able to protect dermal papilla cells from UVB exposure levels of up to at 0.648 J/cm 2 UVB exposure levels and death of PC-4 treated dermal papilla cells is seen at UVB exposure level of 0.8 J/cm .
  • FIG.10 shows that neither ⁇ -L-glutamyl-Selenomethyl-L-selenocysteine (FIG.10a) nor ⁇ -L-glutamyl-L-Selenomethionine (FIG.10b) by themselves are able to protect dermal papilla cells even at low levels of UVB exposure (0.432 J/cm ).
  • FIG.6 shows that PC-5 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 0.8 J/cm .
  • FIG.7 shows that PC-6 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 1.0 J/cm .
  • FIG.8 shows that PC-7 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 0.8 J/cm .
  • FIG.9 shows that PC-8 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 1.0 J/cm .
  • ⁇ -glucogallin or ⁇ -glucogallin and gallates are able to provide protection of dermal papilla cells only up to UVB exposure levels of 0.432 J/cm .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2012/038772 2012-05-07 2012-05-21 Synergistic selenopeptide formulations for the protection of dermal papilla cells Ceased WO2013169273A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RU2014144521A RU2606752C2 (ru) 2012-05-07 2012-05-21 Синергические селенопептидные препараты для защиты дермальных сосочковых клеток
CA2872535A CA2872535C (en) 2012-05-07 2012-05-21 Synergistic selenopeptide formulations for the protection of dermal papilla cells
BR112014027717A BR112014027717A2 (pt) 2012-05-07 2012-05-21 formulações sinérgicas de selenopeptídios para a proteção de células da papila dérmica
MX2014013460A MX355546B (es) 2012-05-07 2012-05-21 Formulaciones de selenopeptido sinergico para la proteccion de celulas de papilas dermicas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/465,873 2012-05-07
US13/465,873 US9498423B2 (en) 2012-05-07 2012-05-07 Synergistic selenopeptide formulations for the protection of dermal papilla cells

Publications (1)

Publication Number Publication Date
WO2013169273A1 true WO2013169273A1 (en) 2013-11-14

Family

ID=46320777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/038772 Ceased WO2013169273A1 (en) 2012-05-07 2012-05-21 Synergistic selenopeptide formulations for the protection of dermal papilla cells

Country Status (11)

Country Link
US (1) US9498423B2 (enExample)
EP (1) EP2695603B1 (enExample)
JP (1) JP6064274B2 (enExample)
AU (1) AU2012203148B2 (enExample)
BR (1) BR112014027717A2 (enExample)
CA (1) CA2872535C (enExample)
MX (1) MX355546B (enExample)
MY (1) MY168089A (enExample)
PL (1) PL2695603T3 (enExample)
RU (1) RU2606752C2 (enExample)
WO (1) WO2013169273A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744260A (zh) * 2015-04-09 2015-07-01 中国水产科学研究院南海水产研究所 一种采用高速逆流色谱从海刀豆中分离多酚单体的方法
WO2022068784A1 (zh) * 2021-05-08 2022-04-07 暨南大学 具有神经元保护功能的富硒蛹虫草活性硒肽及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018501607B1 (en) * 2016-02-24 2023-02-10 Sami Labs Ltd Adaptogenic compositions and applications thereof
US20190060337A1 (en) * 2017-08-31 2019-02-28 Muhammed Majeed Compositions comprising beta-glucogallin and therapeutic applications thereof in controlled kinetics of carbohydrate breakdown and monosaccharide absorption
CN111662868B (zh) * 2020-07-20 2021-03-30 北京达尔文细胞生物科技有限公司 一种cxcr4激动剂及在脐带间充质干细胞体外培养方面的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US20080026017A1 (en) * 2006-05-18 2008-01-31 Muhammed Majeed Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof
US20110033565A1 (en) * 2009-08-07 2011-02-10 Muhammed Majeed Protective Compositions for Dermal Papilla Cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240126A1 (en) * 2003-10-09 2006-10-26 Muhammed Majeed Compositions containing allium sativum linn. (garlic) naturally enriched with organic selenium compounds for nutritional supplementation
NZ552027A (en) * 2004-08-02 2009-10-30 Sami Labs Ltd Compositions and methods for the management of hyperproliferative dermatological conditions
US20110003773A1 (en) * 2008-03-03 2011-01-06 Luna Innovations Incorporated Using fullerenes to enhance and stimulate hair growth
US20100062989A1 (en) * 2008-09-10 2010-03-11 Muhammed Majeed OPTIMAL BIOLOGICAL MARKER FOR THE BIOLOGICAL POTENCY OF Emblica Officinalis Gaertn. (AMLA) FRUIT-METHODS AND PRODUCTS THEREOF
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US20080026017A1 (en) * 2006-05-18 2008-01-31 Muhammed Majeed Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof
US20110033565A1 (en) * 2009-08-07 2011-02-10 Muhammed Majeed Protective Compositions for Dermal Papilla Cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744260A (zh) * 2015-04-09 2015-07-01 中国水产科学研究院南海水产研究所 一种采用高速逆流色谱从海刀豆中分离多酚单体的方法
WO2022068784A1 (zh) * 2021-05-08 2022-04-07 暨南大学 具有神经元保护功能的富硒蛹虫草活性硒肽及其制备方法和应用

Also Published As

Publication number Publication date
JP6064274B2 (ja) 2017-01-25
US9498423B2 (en) 2016-11-22
NZ600307A (en) 2013-11-29
AU2012203148B2 (en) 2018-03-15
RU2606752C2 (ru) 2017-01-10
RU2014144521A (ru) 2016-06-27
JP2013234164A (ja) 2013-11-21
CA2872535C (en) 2017-11-28
US20130295668A1 (en) 2013-11-07
MX355546B (es) 2018-04-19
AU2012203148A1 (en) 2013-11-21
EP2695603A3 (en) 2014-08-06
EP2695603A2 (en) 2014-02-12
EP2695603B1 (en) 2017-05-24
BR112014027717A2 (pt) 2017-06-27
MY168089A (en) 2018-10-11
MX2014013460A (es) 2015-05-07
CA2872535A1 (en) 2013-11-14
PL2695603T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
CA2872535C (en) Synergistic selenopeptide formulations for the protection of dermal papilla cells
JP2017513823A (ja) 酸化ストレスを軽減させる局所用組成物及び方法
EP2977446A1 (en) Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method
JP6846422B2 (ja) Ｐａｌｍａｒｉａ ｐａｌｍａｔａとジャスミンとの相乗作用的抽出物、それを含む組成物およびそれらの使用
Tan et al. Tualang honey improves human corneal epithelial progenitor cell migration and cellular resistance to oxidative stress in vitro
KR20200067973A (ko) 피부 세포 노화의 지연, 피부의 컨디셔닝, 피부암의 치료 및 예방에 있어서 아이스플랜트 캘러스 추출물의 용도
KR20170122317A (ko) 미선나무 추출액을 이용한 탈모방지용 샴푸 조성물
KR20200049714A (ko) 두충나무 껍질 추출물을 함유하는 피부 쿨링 또는 피부 홍조 완화용 화장료 조성물
KR101991601B1 (ko) Sirt6 활성화제 및 dna 복구 효소를 포함하는 조성물
KR101601024B1 (ko) 소나무 뿌리 추출물을 함유하는 피부 외용제 조성물
JP2013147479A (ja) 幹細胞賦活化剤
AU2021275500B2 (en) Protein hydrolysate of Moringa Peregrina Seed Cake for Its Application as a Medicament, Process for Obtaining Same and Pharmaceutical and Dermatological Compositions
WO2013005281A1 (ja) 血小板由来成長因子－ｂｂ産生亢進剤、並びにそれを含む間葉系幹細胞産生促進剤、幹細胞安定化剤、及び真皮再生化剤
KR102695809B1 (ko) 안티-에이징 및 피부 재생 특성을 가지는 피츠로야 쿠프레소이데스(알레르세)의 세포로부터의 수용 추출물(aqueous extract from cells of fitzroya cupressoides (alerce) with anti-aging and skin regeneration properties)
AU2010326651B2 (en) Protective compositions for dermal papilla cells
HK1193758A (en) Synergistic selenopeptide formulations for the protection of dermal papilla cells
JP2013155122A (ja) 幹細胞賦活化剤
HK1193758B (en) Synergistic selenopeptide formulations for the protection of dermal papilla cells
US20150328137A1 (en) Vegfc production promoter
NZ600307B (en) Synergistic selenopeptide formulations for the protection of dermal papilla cells
US10463700B2 (en) Use of propolis for combating the side effects of chemotherapy
ES2687458T3 (es) Composición que comprende un extracto de Chelidonium majus y Copaiba, y uso de la misma para el tratamiento de disfunciones cutáneas
Wang et al. Hyperbaric Oxygen Combined with Alginate Oligosaccharide Delay D-gal-induced Liver, Kidney and Spleen Senescence in Mice by Attenuating Oxidative Stress
KR20170032624A (ko) 시네라리아 추출물 및 이를 포함하는 화장료 조성물
KR20060066181A (ko) 피부 노화를 억제하는 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12876384

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2872535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/013460

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: P1207/2014

Country of ref document: AE

ENP Entry into the national phase

Ref document number: 2014144521

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014027717

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 12876384

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112014027717

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141106